Technology

Our proprietary peptide technology platform is built on a series of tools and methods which allow us to discover and develop structurally novel oral or injectable peptides as potential product candidates. The platform utilizes these tools and techniques in an integrated and iterative manner in synergy with our deep-rooted expertise in peptide-engineering, which allows us to derive products with the desired potency, selectivity, oral or plasma stability, PK, and physicochemical properties. These tools and techniques include, but are not limited to, the following:

  • Molecular design tools and large virtual libraries of constrained scaffolds, collectively known as Vectrix: Allows for the de novo selection of peptide scaffolds as starting points against specific targets based on computational matching to functional structures of the intended targets.
  • Random libraries and phage display techniques: Allows for the discovery and optimization of peptide hits in a de novo and/or focused manner.
  • Oral stability assays: In vitro and ex vivo assays and systems that simulate chemical and biological degradative mechanisms, and physical barriers that constrained peptides must overcome for oral stability and absorption.
  • Formulation: Integration of known and novel technologies to deliver stable peptides through oral, subcutaneous, and rectal dosage forms to optimize treatment options for patients.
  • Medicinal peptide chemistry: Allows optimization and refinement of potency, selectivity, oral stability and GI restriction.
  • In vivo and ex vivo pharmacology studies for GI restriction: Tools to quantify compound concentrations and activity in various GI tissue compartments to develop oral products with GI stability and minimal systemic exposure.

To date, our platform has generated two oral antagonist peptide candidates, PTG-100 and PTG-200, for IBD, and an injectable hepcidin peptide mimetic, PTG-300, for anemia and iron overload disorders, exemplifying our platform’s reproducibility and broad scope. We will continue to use our technology platform to discover novel peptides against targets where small molecules or injectable biologics do not present viable opportunities for drug discovery or offer satisfactory outcomes to patients.

Back to top